TScan Therapeutics Inc (TCRX): Koefisien rega marang pendapatan
High R&D costs and strict FDA regulations create an insurmountable barrier to entry for competitors of TScan Therapeutics (TCRX). The revenue multiple dynamics illustrate the current market status, where the 1.50 level indicates the state of the parameter. Growth is driven by successes in TCR-T trials and interest from pharma behemoths, while development is supported by a team of experts motivated by financial incentives and scientific freedom.
TScan Therapeutics (TCRX) - rincian metrik lan laporan keuangan
- kuotasi lan prakiraan analis:
- data kapitalisasi bursa:
- rincian nilai buku perusahaan:
- statistik kawajiban utang lan likuiditas:
Rasio Utang marang Ekuitas TScan Therapeutics|TCRX - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal tscan.com|TCRX - Gunggung utang perusahaan|Utang marang modal buku TScan|TCRX - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan TScan Therapeutics|Likuiditas darurat tscan.com
- data bathi bisnis lan rasio investasi:
TCRX - Bathi resik perusahaan|Penghasilan resik sing dikarepake TScan Therapeutics|TCRX - Pangali P/E|Pangali Forward P/E tscan.com|TCRX - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan TScan|TCRX - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan TScan Therapeutics|TCRX - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan tscan.com|TCRX - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep TScan Therapeutics
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:TScan Therapeutics Inc
The P/S multiple determines the market value of a business relative to its annual revenue, measuring the premium for future growth. This calculation compares market capitalization with actual cash flows to identify whether assets are overvalued or undervalued. By analyzing the current P/S level on the GURU.Markets platform, an investor assesses the balance between risk and return potential. For TScan Therapeutics (TCRX), this indicator reflects market expectations regarding the scaling of solid tumor therapies.
Perusahaan pesaing
Kapitalisasi marang volume dodolan ONC|Rasio rega marang pendapatan Halozyme HALO|Koefisien rega marang pendapatan Revolution Medicines Inc (RVMD)|Ascentage - Multiplikator P/S|CG Oncology Therapeutics (CGON) - Kapitalisasi marang pendapatan|URGN: Multiplikator P/S|bicara.com (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan Personalis|Rasio kapitalisasi marang pendapatan ERAS (Erasca Inc)|Kapitalisasi marang pendapatan DCTH (Delcath)|YMAB (Y-mAbs Corp) - Rasio kapitalisasi pasar marang pendapatan|Aura Biosciences, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan CADL (Candel Therapeutics Inc.)|Accuray - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan SLS (SELLAS Life Sciences)|ACTU: Multiplikator P/S|Rega marang dodolan Citius Oncology Inc (CTOR)|Rasio rega marang pendapatan TuHURA Biosciences Inc.|TARA: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S FATE|Multiplikator P/S aadibio.com (WHWK)|Rasio rega marang pendapatan Champions Oncology, Inc. CSBR|XBIT (XBiotech Inc) - Rasio rega marang dodolan|CEL-SCI Corp - Multiplikator P/S|Rega marang dodolan ostherapies.com|RADX (Radiopharm Theranostics) - Kapitalisasi marang pendapatan|Artiva Biotherapeutics (ARTV) - Multiplikator P/S|Kapitalisasi marang pendapatan ANL|VERU (Veru Corporation) - Kapitalisasi marang volume dodolan|Multiplikator P/S TPST|Koefisien rega marang pendapatan xiliotx.com|Multiplikator P/S RENB (Renovaro)|MURA - Kapitalisasi marang pendapatan|KAPA - Rasio rega marang pendapatan|Koefisien rega marang pendapatan OnKure Therapeutics Inc OKUR|GDTC (w2.cytomed.sg) - Kapitalisasi marang pendapatan|CRIS: Kapitalisasi marang volume dodolan|APLM (Apollomics Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Inc (THAR)|Rasio rega marang pendapatan Advanced Biomed Inc (ADVB)|GNPX (Genprex Inc) - Rasio kapitalisasi pasar marang pendapatan|Calidi Biotherapeutics, Inc. - Kapitalisasi marang pendapatan|SBFM: Rasio kapitalisasi marang pendapatan|Xenetic Bio - Multiplikator P/S|Salarius Pharmaceuticals Inc (SLRX) - Kapitalisasi marang pendapatan|PPBT: Multiplikator P/S|American Oncology Network, Inc. (AONC) - Multiplikator P/S|Rasio rega marang pendapatan BeiGene, Ltd.|Rasio kapitalisasi marang pendapatan CKPT (checkpointtx.com)|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan icadmed.com ICAD|Multiplikator P/S IKNA (Ikena Oncology)|Notable Labs Corp (NTBL) - Rega marang dodolan|VIRX - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MOR (morphosys.com)|NAYA (NAYA Biosciences Inc.) - Kapitalisasi marang pendapatan|Ascentage Pharma Group International - Rasio kapitalisasi pasar marang pendapatan
